Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(4)
Filter by content year
(-)
2024
(4)
Filter by form group
Filter by category
(-)
Other
(4)
Clinical
(2)
Financial
(2)
Science
(2)
Filter by category
Search
News
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305
News
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
News
BioNTech stellt strategische Prioritäten für 2024 auf der 42. jährlichen J.P. Morgan Healthcare-Konferenz vor
News
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference